NEW YORK -- Irish drugmaker Jazz Pharmaceuticals PLC said Monday that it completed the sale of its women's health business to Swedish pharmaceutical company Meda AB.
Jazz agreed to sell the business to Meda in September for $95 million in cash. In the deal Meda acquired the estradiol gel Elestrin, the menopause symptom treatment Gastrocrom, prenatal vitamin Natelle One, AVC Cream, prenatal multivitamin Gesticare DHA and urinary antiseptic Urelle. Jazz said sales of the products totaled $30.4 million in 2011.
Jazz said it sold the business so it could focus on its core products.
Shares of Jazz Pharmaceuticals rose 89 cents to close at $57.03.